ArticleHepatology (Baltimore, Md.)2019
17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease.
Open access · greenAbstract read
In one paragraph
Article in Hepatology (Baltimore, Md.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 163 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
163citing papers in PubMed, 5 pooled it
22.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
163 citing papers in PubMed, 5 syntheses or guidelines pooled it, 297 citations in OpenAlex.
- Meta-Analysis of Genetic Variants Associated With HBV Infection Susceptibility and Hepatocellular Carcinoma Risk.Journal of viral hepatitis · 2026Pooled it
- Meta-Analysis: Effects of Steatotic Liver Disease-Associated Genetic Risk Alleles on Longitudinal Outcomes.Alimentary pharmacology & therapeutics · 2025Pooled it
- Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease.Nature genetics · 2023Pooled it
- Association of HSD17B13 rs72613567: TA allelic variant with liver disease: review and meta-analysis.BMC gastroenterology · 2021Pooled it
- Identification of prognostic lipid droplet-associated genes in pancreatic cancer patients via bioinformatics analysis.Lipids in health and disease · 2021Pooled it
- Genetic and genomic insights across the steatotic liver disease spectrum.Clinical and molecular hepatology · 2026Review
- Molecular mechanisms and pathogenesis of MASH.Nature · 2026Review
- Beyond Fat: Reframing MASLD Through Genetics, Clonal Biology, and Precision Hepatology.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Hepatic Lipoprotein Production, Cardiometabolic Phenotypes, and Subtypes of Steatotic Liver Disease.Circulation research · 2026Review
- Membrane bridges and nanodomain partitioning govern membrane protein targeting to lipid droplets.Nature cell biology · 2026Article
- Integrating CRISPR genome editing with liver organoid and hiPSC-derived microfluidic platforms to model metabolic dysfunction-associated steatotic liver disease.Biochemistry and biophysics reports · 2026Review
- Germline mutations and somatic mosaicism in steatotic liver diseases and related liver carcinogenesis.Nature reviews. Gastroenterology & hepatology · 2026Review
- Loss of the E3 ubiquitin ligase MARCHF6 alters hepatic lipid metabolism and drives spontaneous hepatosteatosis.Molecular metabolism · 2026Article
- Disease-driven loss of inactive HSD17B13 isoforms enhances enzymatic output in MASH and counters protective rs72613567:TA variant.JHEP reports : innovation in hepatology · 2026Article
- Hepatotoxicity induced by polylactic acid microplastics: The mediating role of gut microbiota and uric acid metabolism.Journal of advanced research · 2026Article
- Metabolic dysfunction-associated steatotic liver disease and steatohepatitis-associated hepatocarcinoma preclinical models.Nature reviews. Gastroenterology & hepatology · 2026Review
- Genetic and non-genetic drivers of histological progression and regression in MASLD.Journal of hepatology · 2026Article
- Single cell multiomic landscape reveals gene programs driving lipid droplet heterogeneity in hepatic steatosis.Scientific reports · 2026Article
- A Global Perspective on Metabolic Dysfunction-Associated Steatotic Liver Disease: From Molecular Mechanisms to Therapeutic Strategy Innovation.Nutrients · 2026Review
- Genetic Predisposition to MASLD: Potential for Therapeutic Management.International journal of molecular sciences · 2026Review
103 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on byREPLY.2020
Authors and funding
22 authors at 5 institutions in 1 country.
Yanling MaLiver and Energy Metabolism Unit, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Olga V BelyaevaDepartment of Biochemistry and Molecular Genetics, Schools of Medicine and Dentistry, University of Alabama-Birmingham, Birmingham, AL.
Philip M BrownLiver and Energy Metabolism Unit, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Koji FujitaLiver and Energy Metabolism Unit, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Katherine VallesLiver and Energy Metabolism Unit, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Suman KarkiDepartment of Biochemistry and Molecular Genetics, Schools of Medicine and Dentistry, University of Alabama-Birmingham, Birmingham, AL.
Ynto S de BoerLiver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Christopher KohLiver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Yanhua ChenDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI.
Xiaomeng DuDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI.
Samuel K HandelmanDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI.
Vincent ChenDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI.ORCID 0000-0002-0157-6066
Elizabeth K SpeliotesDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI.
Cara NestlerodeDepartment of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA.
Emmanuel ThomasLiver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
David E KleinerLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Joseph M ZmudaDepartment of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA.
Arun J SanyalDepartment of Internal Medicine, Division of Gastroenterology, Virginia Commonwealth University, Richmond, VA.
(for the Nonalcoholic Steatohepatitis Clinical Research Network)
Natalia Y KedishviliDepartment of Biochemistry and Molecular Genetics, Schools of Medicine and Dentistry, University of Alabama-Birmingham, Birmingham, AL.
T Jake LiangLiver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Yaron RotmanLiver and Energy Metabolism Unit, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.ORCID 0000-0002-7549-8216
National Institutes of Health · USUniversity of Michigan · USUniversity of Alabama at Birmingham · USUniversity of Pittsburgh · USVirginia Commonwealth University · US
Funding
Transform Dissemination and Implementation Science in CTSA ProgramsUL1TR002319 · NCATS · UNIVERSITY OF WASHINGTON · PI John K. Amory · 2017 to 2026
$100.0MWU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8MEngaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0MClinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0MInstitute of Translational Health SciencesUL1TR000423 · NCATS · UNIVERSITY OF WASHINGTON · PI DISIS, MARY L. · 2012 to 2016
$49.4MWashington University Institute of Clinical and Translational SciencesUL1TR000448 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$41.4MClinical and Translational Science Collaborative of ClevelandUL1TR002548 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI MCCOMSEY, GRACE A · 2018 to 2022
$35.5MPediatric Trials in Non-Alcoholic Steatohepatitis (NASH)U01DK061734 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ROHIT LOOMBA · 2002 to 2026
$24.4MContinuation of the Non-Alcoholic Steatohepatitis Clinical Research Network (NASHU01DK061730 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI TONASCIA, JAMES A · 2002 to 2018
$23.2MSan Diego Clinical and Translational Research InstituteUL1TR000100 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S · 2012 to 2015
$19.7MNonalcoholic Steatohepatitis: Natural History, Pathogenesis and TherapyZIADK075013 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI ROTMAN, YARON · 2009 to 2025
$19.1MTherapy, Vaccine and Model Development in Viral Hepatitis and Liver DiseasesZIADK054505 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI LIANG, T. JAKE · 2009 to 2025
$17.5MIntramural NIH HHS Z99 DK999999Intramural NIH HHS ZIA DK075013NCATS NIH HHS UL1 TR000004NCATS NIH HHS UL1 TR000006NCATS NIH HHS UL1 TR000058NCATS NIH HHS UL1 TR000100NCATS NIH HHS UL1 TR000423NCATS NIH HHS UL1 TR000436NCATS NIH HHS UL1 TR000439NCATS NIH HHS UL1 TR000448NCATS NIH HHS UL1 TR002319NCATS NIH HHS UL1 TR002345NCATS NIH HHS UL1 TR002548NCI NIH HHSNIAAA NIH HHS R01 AA012153NIDDK NIH HHS R01 DK106621NIDDK NIH HHS R01 DK107904NIDDK NIH HHS U01 DK061713NIDDK NIH HHS U01 DK061718NIDDK NIH HHS U01 DK061728NIDDK NIH HHS U01 DK061730NIDDK NIH HHS U01 DK061731NIDDK NIH HHS U01 DK061732NIDDK NIH HHS U01 DK061734NIDDK NIH HHS U01 DK061737NIDDK NIH HHS U01 DK061738NIGMS NIH HHS R35 GM124915NIH HHS R01 DK106621NIH HHS R01 DK107904NLM NIH HHS HHSN276201200017C
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease. A single-nucleotide polymorphism (SNP), rs6834314, was associated with serum liver enzymes in the general population, presumably reflecting liver fat or injury. We studied rs6834314 and its nearest gene, 17-beta hydroxysteroid dehydrogenase 13 (HSD17B13), to identify associations with histological features of NAFLD and to characterize the functional role of HSD17B13 in NAFLD pathogenesis. The minor allele of rs6834314 was significantly associated with increased steatosis but decreased inflammation, ballooning, Mallory-Denk bodies, and liver enzyme levels in 768 adult Caucasians with biopsy-proven NAFLD and with cirrhosis in the general population. We found two plausible causative variants in the HSD17B13 gene. rs72613567, a splice-site SNP in high linkage with rs6834314 (r
Indexed as
17-Hydroxysteroid DehydrogenasesAdultAmino Acid SequenceCohort StudiesFemaleHEK293 CellsHep G2 CellsHumansLiverMaleMiddle AgedMolecular Targeted TherapyNon-alcoholic Fatty Liver DiseasePolymorphism, Single NucleotideRetinoids17-Hydroxysteroid DehydrogenasesHSD17B13 protein, humanRetinoids
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.